[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563228":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":112,"collaborators":26,"id":114,"slug":115,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":26,"eligibilityCriteria":120,"healthyVolunteers":116,"sex":121,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":26,"studyType":127,"phases":128,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":54,"whyStopped":26,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"Gerd Care Medical Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active","EXPERIMENTAL","Participants in the active arm will be using a functional version of the investigational device for 28 days.",[13],"Device: eGERD device",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","SHAM_COMPARATOR","Participants in the control arm will be using a sham version of the investigational device for 28 days.",[19],"Device: eGERD_Sham",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","eGERD device","The eGERD device is a novel device developed by GerdCare Medical for reducing symptoms of GERD. The device is noninvasive and designed for self-use in the home environment. It is applied on the abdominal skin and generates electrical stimulation pulses.\n\nFor optimized effect, the stimulation is synchronized with the breathing phase, such that it is active mainly during inhalation. The stimulation intensity can be adjusted by the user.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"eGERD_Sham","The eGERD\\_Sham is a sham version of the eGERD device. It is capable of inducing sensation of electrical stimulation pulses in the target abdominal muscles without a therapeutic effect. Aside from this difference, the eGERD\\_Sham is identical to the eGERD device.",[15],[32,52,70,84,98],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Division of Gastroenterology & Hepatology Feinberg School of Medicine Northwestern University","NOT_YET_RECRUITING","Chicago","Illinois","60611-2927","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-87.65005,41.85003,{"lat":44,"lon":43},[47],{"name":48,"role":49,"phone":50,"phoneExt":26,"email":51},"Ofer Z Fass, MD","CONTACT","312.695.0182","ofer.fass@northwestern.edu",{"facility":53,"status":54,"city":55,"state":26,"zip":26,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Gastroenterology department, Emek medical center (EMC)","RECRUITING","Afula","Israel","IL",{"type":41,"coordinates":59},[60,61],35.2892,32.60907,{"lat":61,"lon":60},[64,68],{"name":65,"role":49,"phone":66,"phoneExt":26,"email":67},"Fahmi Shibli, MD","972544508118","fahmi_sh@clalit.org.il",{"name":65,"role":69,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"facility":71,"status":54,"city":72,"state":26,"zip":26,"country":56,"countryCode":57,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Gastroenterology department, Rambam Health Care Campus","Haifa",{"type":41,"coordinates":74},[75,76],34.99928,32.81303,{"lat":76,"lon":75},[79,83],{"name":80,"role":49,"phone":81,"phoneExt":26,"email":82},"Rita Brun, MD","972502061142","r_brun@rambam.health.gov.il",{"name":80,"role":69,"phone":26,"phoneExt":26,"email":26},{"facility":85,"status":54,"city":86,"state":26,"zip":26,"country":56,"countryCode":57,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Gastroenterology department, Rabin medical center (RMC)","Petah Tikva",{"type":41,"coordinates":88},[89,90],34.88747,32.08707,{"lat":90,"lon":89},[93,97],{"name":94,"role":49,"phone":95,"phoneExt":26,"email":96},"Ram Dickman, Prof.","972523428692","dickmanr@clalit.org.il",{"name":94,"role":69,"phone":26,"phoneExt":26,"email":26},{"facility":99,"status":54,"city":100,"state":26,"zip":26,"country":56,"countryCode":57,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Gastroenterology department, Tel Aviv Sourasky Medical Center (Ichilov)","Tel Aviv",{"type":41,"coordinates":102},[103,104],34.78057,32.08088,{"lat":104,"lon":103},[107,111],{"name":108,"role":49,"phone":109,"phoneExt":26,"email":110},"Yoav Mazor, MD","97236974281","yoavmaz@tlvmc.gov.il",{"name":108,"role":69,"phone":26,"phoneExt":26,"email":26},{"type":113,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100563228","safety-and-effectiveness-of-egerd-device-to-reduce-gastroesophageal-reflux-disease-gerd-symptoms-100563228",false,"NCT06613438","Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms","The Effect of Non-Invasive Electrical Stimulation Therapy on Gastroesophageal Reflux Disease (GERD)","Inclusion Criteria:\n\n1. Male or female, aged 22 - 75\n2. Has been typically suffering from at least three heartburn and\u002For regurgitation episodes per week during the past three months.\n3. Undergone a wireless (Bravo) pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2) in at least 2 monitoring days AND when averaged over all monitoring days of the test; or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD; or Undergone a catheter-based pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2); or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD.\n4. Able and willing to give informed consent for participation in the study and to comply with all study requirements, including operating the smartphone application.\n5. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.\n\nExclusion Criteria:\n\n1. Previously undergoing gastric or esophageal surgery\n2. Active peptic ulcer disease or symptomatic helicobacter\n3. Esophageal or gastric varices or esophageal peptic stricture\n4. Severe dysphagia\n5. History of suspected or confirmed esophageal or gastric cancer\n6. History of any other malignancy in the last 2 years\n7. Pregnant women or women intending to become pregnant during the trial period\n8. Uncontrolled diabetes mellitus, defined as HbA1c \\> 7.5%\n9. Severe cardiac conditions such as cardiac arrhythmia or ischemia or cardiac pacemaker \u002F defibrillator\n10. Having any implanted electrical device (e.g. sacral nerve stimulation, brain stimulator, others)\n11. Known allergy to the device's adhesives\u002Fpatches\n12. Severe pulmonary diseases\n13. History of significant multisystem diseases (e.g. kidney failure, liver failure)\n14. Known autoimmune or a connective tissue disorder (e.g. scleroderma, CREST-syndrome, Sjogren's Syndrome), requiring therapy in the preceding 2 years\n15. History of Barrett's esophagus\n16. Para-esophageal hiatal hernia\n17. Known history of sliding hiatal hernia ≥4 cm in the last 3 years\n18. Known history of erosive esophagitis Grade C or D (LA classification) in the past 5 years\n19. Obesity, defined as BMI\\>32\n20. History of gastroparesis\n21. History of fibromyalgia, epilepsy, endometriosis\n22. Umbilical hernia \\>3cm\n23. Past usage experience with the study device\n24. Those currently enrolled in any other interventional clinical study\n25. Inability to sign the informed consent\n26. Inability to understand and fill the reports and questionnaires included in the study\n27. Inability to follow the study requisites\n28. Other medical conditions\u002Fmedications that would interfere with subject safety or data collection in the opinion of the PI","ALL","22 Years","75 Years",{"count":125,"type":126},84,"ESTIMATED","INTERVENTIONAL",[129],"NA","The purpose of this research is to evaluate the safety and effectiveness of the eGERD device, which is a novel device for treating Gastroesophageal Reflux Disease (GERD).\n\nThe main questions this research aims to answer are:\n\n1. Does the eGERD device reduce acidity in the esophagus?\n2. Does the eGERD device reduce GERD symptoms such as heartburn and regurgitation?\n3. What medical problems do participants have when using the eGERD device?\n\nTo assess the acidity in the esophagus, a wireless standard-of-care capsule called Bravo will be placed in the participants esophagus (throat) for several days.\n\nTo assess GERD symptoms, participants will be requested to report symptoms they experience using a smartphone application.\n\nResearchers will compare a real version of the eGERD device to a sham version (a look-alike device that has no therapeutic effect) to see if the eGERD device is effective in treating GERD.",[132],"GERD (Gastroesophageal Reflux Disease)",[134,135,136,137],"Electrostimulation","Refulx","Regurgitation","eGERD","2026-06-22",{"date":140,"type":141},"2026-06-23","ACTUAL",{"date":143,"type":141},"2024-09-15",{"date":145,"type":126},"2027-04",{"name":5,"class":6},5]